Fulcrum Therapeutics Stock Forward View - Triple Exponential Smoothing
| FULC Stock | USD 7.43 -0.01 -0.13% |
The Triple Exponential Smoothing reference data for Fulcrum Therapeutics is derived from the equity's published trading history. Forecast values and accuracy indicators are summarized on this page for reference.
The Triple Exponential Smoothing forecasted value of Fulcrum Therapeutics on the next trading day is expected to be 7.34 with a mean absolute deviation of 0.33 and the sum of the absolute errors of 19.36.As with simple exponential smoothing, in triple exponential smoothing models past Fulcrum Therapeutics observations are given exponentially smaller weights as the observations get older. In other words, recent observations are given relatively more weight in forecasting than the older Fulcrum Therapeutics observations. All forecast values on this page for Fulcrum Therapeutics are Triple Exponential Smoothing reference data derived from historical price series. Triple Exponential Smoothing Price Forecast For the 18th of March 2026
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Fulcrum Therapeutics on the next trading day is expected to be 7.34 with a mean absolute deviation of 0.33 , mean absolute percentage error of 0.24 , and the sum of the absolute errors of 19.36 .Please note that although there have been many attempts to predict Fulcrum Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Fulcrum Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Fulcrum Therapeutics | Fulcrum Therapeutics Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Fulcrum Therapeutics uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. At the moment, the model places downside around 2.87 and upside around 11.81 for the forecasting period.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Fulcrum Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Fulcrum Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | 0.0783 |
| MAD | Mean absolute deviation | 0.3282 |
| MAPE | Mean absolute percentage error | 0.0329 |
| SAE | Sum of the absolute errors | 19.3645 |
Other Forecasting Options for Fulcrum Therapeutics
For both new and experienced investors in Fulcrum, the ability to analyze Fulcrum Therapeutics' price movement is a fundamental investment skill. Price chart noise in Fulcrum Stock can create false signals and mislead investment decisions.Fulcrum Therapeutics Related Equities
The following equities are related to Fulcrum Therapeutics within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Fulcrum Therapeutics against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Fulcrum Therapeutics Market Strength Events
Tracking market strength indicators for Fulcrum Therapeutics helps investors understand the momentum dynamics of the stock in real time. These signals support informed decisions about when to enter or exit positions in Fulcrum Therapeutics for maximum return potential.
Fulcrum Therapeutics Risk Indicators
Properly assessing Fulcrum Therapeutics' risk indicators is a prerequisite for building reliable price forecasts. Identifying and quantifying the risks associated with Fulcrum Therapeutics' allows investors to make better-informed decisions about accepting or hedging their exposure.
| Mean Deviation | 3.15 | |||
| Standard Deviation | 4.4 | |||
| Variance | 19.4 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Fulcrum Therapeutics
Story coverage around Fulcrum Therapeutics often expands when market conditions, narrative momentum, or risk-adjusted performance make the security more visible to investors. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Fulcrum Therapeutics Short Properties
Short-interest signals around Fulcrum Therapeutics can help investors judge whether skeptical positioning is starting to pressure price predictability and market tone. This is most valuable when investors want to know whether bearish pressure is starting to shape the market's reaction function.
| Common Stock Shares Outstanding | 63.4 M | |
| Cash And Short Term Investments | 352.3 M |